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MTH is now part of post-resuscitation care after a witnessed cardiac arrest due to VF/VT,
and offers evidence of improved neurological outcomes and survival. The evidence of MTH
benefits in patients with non-shockable rhythms is less certain. The second part of this
review is dedicated to MTH, which focuses on randomized and non-randomized clinical
trials, as well as observational registries that have studied the efficacy of MTH following
cardiac arrest in different patient populations
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The majority of patients who survive out-of-hospital cardiac
arrest (OHCA) usually develop some degree of neurologicalech Society of Cardiologydisability caused by ischemia-reperfusion cerebral injury [1].
Favorable outcomes in patients admitted to hospitals after a
successful return of spontaneous circulation (ROSC) following
a OHCA, range from 11% to 48% [2].. Published by Elsevier Urban & Partner Sp. z.o.o. All rights
c o r e t v a s a 5 4 ( 2 0 1 2 ) e 2 4 3 – e 2 4 7e244Some clinical trials have tried to demonstrate beneficial
effects of drugs such as barbiturates [3], magnesium, steroids
[4] and calcium-channel antagonists [5] in reducing neurologi-
cal impairment in patients after cardiac arrest. Unfortunately,
the results of these studies showed no benefit from these drugs.
With the administration of mild therapeutic hypothermia
(MTH) following resuscitation after cardiac arrest, we see for
the first time, that the neurological recovery of these patients
has improved, and mortality has decreased.
The second part of this review is dedicated to MTH, which
focuses on randomized and non-randomized clinical trials,
as well as observational registries that have studied the
efficacy of MTH following cardiac arrest in different patient
populations.2. Cardiac Arrest due to Ventricular
Fibrillation/Pulseless Ventricular Tachycardia
In 2002, two prospective randomized clinical studies [6,7]
were published which compared the outcomes in comatose
survivors after OHCA with, or without, hypothermia.
One of these studies [6] was organized in conjunction with
nine centers in five European countries. A total of 3551
patients were assessed as eligible for the trial and 275
patients were enrolled. The inclusion criteria were: witnessed
cardiac arrest, ventricular fibrillation/ pulseless ventricular
tachycardia (VF/VT), time intervals of 5 to 15 min from
collapse to resuscitation, and a time interval of no more than
60 min from collapse to ROSC. Exclusion criteria were: a
tympanic-membrane temperature below 30 1C on admission,
pregnancy, response to verbal commands after ROSC, a mean
arterial pressure of less than 60 mmHg for more than 30 min
following ROSC, evidence of hypoxemia longer than 15 min
after ROSC, terminal illness, and preexisting coagulopathy.
All patients received standard intensive care. Sedation was
induced using midazolam and fentanyl. Shivering paralysis
was induced by intravenous administration of pancuronium.
Temperature measurements were made using a bladder
temperature probe. Patients randomly assigned to the group
with hypothermia were cooled to a target temperature of
32 1C to 34 1C for 24 h with the use of an external cooling
device. If the goal temperature was not achieved within 4 h
after ROSC, ice packs were applied. Passive re-warming took
8 h. The primary outcome was a favorable neurological out-
come within 6 months, defined as either a Pittsburgh Cere-
bral-Performance Category (CPC) 1 (good recovery) or 2
(moderate disability). Secondary end points were overall
mortality at 6 months and the rate of complications during
the first 7 day following cardiac arrest. Bleeding of any
severity, pneumonia, sepsis, pancreatitis, renal failure,
pulmonary edema, seizures, arrhythmias and blood pressure
were also recorded.
In this trial, 137 patients were randomly assigned to the
MTH group, and 138 to the group without MTH (w/o MTH). At
six months, a favorable neurological outcome was reached in
55% of patients in the group with MTH, compared with 39% of
patients in the group w/o MTH (p¼0.009). To prevent one
unfavorable neurologic outcome, 6 patients needed to be
treated with MTH. Six months after cardiac arrest, deathoccurred in 41% of patients in the group with MTH and 55% of
patients in the group without (p¼0.02). The rates of compli-
cations did not differ significantly between the two groups
(70% MTH vs. 73% w/o MTH).
The second study [7] was performed in Melbourne,
Australia between 1996 and 1999. In this pseudo-randomized
trial, patients, after cardiac arrest with ROSC, were randomly
assigned either to the MTH group, or the group w/o MTH,
(assignment was based on the day of the month). Inclusion
criteria were cardiac arrest due to VF/VT, ROSC, and persis-
tent coma after ROSC. Patients were excluded if younger than
18 years (for men) and younger than 50 (for women, due to
the possibility of pregnancy), cardiogenic shock, and coma
caused by something other than cardiac arrest. Core body
temperature was monitored via either the tympanic mem-
brane or the urinary bladder, until a pulmonary-artery cathe-
ter was placed. The initial basic cooling was administered in
the ambulance. On hospital arrival MTH was continued using
cold packs on the head, neck, torso and limbs; the target
pulmonary artery temperature was 33 1C, which was main-
tained for 12 h following hospital admission. During cooling,
patients were sedated and paralyzed with midazolam and
vecuronium. Beginning at 18 h, patients were actively
re-warmed for the next 6 h by an external warming device.
The primary outcome was survival to hospital discharge,
with sufficiently good neurological function to be sent either
home or to a rehabilitation facility. The secondary outcomes
included the hemodynamic, biochemical and hematologic
effects of hypothermia.
From a total of 77 patients, 43 were assigned to hypother-
mia and 34 to normothermia. A favorable neurological out-
come occurred nearly twice as often in the group with MTH
(49% of patients) as opposed to the control group (26% of
patients, p¼0.046). The difference in mortality rates between
the two groups did not reach the level of significance (51%
vs. 68%).
Both of these studies investigated the effects of MTH in
patients with ROSC after cardiac arrest when VF was the
initial rhythm. Major limitations were: (a) the inclusion of a
highly select group of patients (based on inclusion/exclusion
criteria, 92% of patients were excluded), (b) physicians were
not blinded to the treatment arm, (c) core temperatures in the
control group were higher than the normal upper range in
the population.3. Cardiac Arrest due to Asystole/Pulseless
Electrical Activity (PEA).
Unlike the evidence in patients where the first documented
rhythm was VF/VT, there is a lack of published data in cardiac
arrest survivors where the initial rhythm was asystole/PEA
(non-shockable rhythm).
Hachimi-Indrissi [8] conducted a feasibility study in which
he investigated the use of MTH in patients with cardiac arrest
due to asystole/PEA and who remained unconscious after
ROSC. In the hypothermia group, a helmet-like device was
placed around the head and neck in order to induce MTH
with a target temperature of 34 1C for a maximum of 4 h. No
additional devices were used to reduce body temperature. 30
Table 1 – Nonrandomized studies of cardiac arrest survivors with a non-shockable initial rhythm.
Author Study type Method of cooling Target
temperature
Duration of
cooling
Survival (hypothermia
vs. control)
Don[21] Retrospective/historical
control subjects
External 32 1C–34 1C 24 h 21% vs. 19%, p¼ns
Oddo[22] Retrospective External 33 1C 24 h 17% vs. 9% p¼ns
Arrich[23] Prospective Endovascular 33 1C 24 h 35% vs. 19% p¼0.02
Testori[2] Retrospective External or endovascular or
combination
32 1C–34 1C 24 h 61% vs. 75% p¼0.025
Lundbye[24] Prospective/historical
control group
Endovascular 32 1C–34 1C 18 h 38% vs. 19% p¼0.03
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6-month period. 16 patients were randomly delegated to the
MTH group and 14 patients were placed in the control group.
The first documented rhythm was asystole in 80% of patients,
and PEA in the remaining 20%. The mortality rate was high in
both patient populations; 81% in the MTH group and 92.8% in
the control group. The authors concluded that MTH induced
using a helmet-like device was feasible, easy to perform,
inexpensive and effective, with no increase in complications.
This study was not able to show a significant advantage in
terms of either the neurological or overall outcomes of
treatment with MTH.
In a study from Kim et al. [9], 125 patients after OHCA
(irrespective of post-arrest ECG) were randomized to cooling
in the field before their arrival to the emergency department
or to standard resuscitation care. In the MTH group
(63 patients), up to 2 l of 4 1C normal saline infusion was
administrated during transport. There was a trend toward
improved survival to discharge in patients randomized to
field cooling when the initial rhythm was VF. The reverse was
observed when the initial rhythm was not VF. However, none
of these differences were statistically significant.
Observational studies in non-shockable OHCA patients pro-
vided conflicting results (Table 1). Dumas et al. [10] described
the prognostic value of MTH in neurological outcomes at
hospital discharge, based with the first-recorded rhythm, in a
large cohort of 1145 patients. Hypothermia was started on
ICU admission, by means of an external cooling device, and
was used during the first 24 h in order to obtain a target
temperature between 32 1C and 34 1C. Over the course of the
study, therapeutic hypothermia was induced in 65% of
patients with VF/VT, and 60% of patients with asystole/PEA.
A good neurological outcome, defined as a CPC 1–2, was
observed at hospital discharge in 30% of all patients.
Hypothermia was associated with a significantly better out-
comes in patients with VF/VT (44% in the group with
hypothermia vs. 29% in the group without hypothermia,
po0.001), but not in patients with asystole/PEA (15% MTH
vs. 17% w/o MTH n.s.). Following multivariable analysis,
hypothermia tended to be inversely associated with a good outcome
(adjusted OR 0.71, 95% CI 0.37–1.36, p¼0.3) in the asystole/
PEA subgroup.
In their meta-analysis of two randomized trials and twelve
non-randomized trials, Kim et al. [11] investigated the effects
of MTH on the survival or neurological outcomes in adult
cardiac arrest survivors with non-shockable initial rhythms.They analyzed randomized and non-randomized studies
separately. The two randomized trials included only 44
subjects and were inconclusive regarding the effects of
MTH on patients with non-shockable initial rhythms.
The non-randomized studies included survival data for 390
subjects and neurological outcomes for 289 subjects treated
with MTH. The pooled results showed that the MTH group
experienced reduced in-hospital mortality in patients resus-
citated from cardiac arrest who presented with non-shock-
able initial rhythms (risk ratio 0.84, 95% CI 0.78–0.92,
po0.0001). The neurological outcome at hospital discharge
had a pooled risk ratio of 0.95 with no statistical difference.
However, most of the studies had very low quality evidence.4. Therapeutic Hypothermia and Coronary
Angiography.
The feasibility and safety of percutaneous coronary interven-
tion (PCI) in conjunction with MTH following cardiac arrest
was studied by Batista et al. [12]. It was a single center study
using a retrospective cohort. A total of 90 adult comatose
patients, who presented between 0 and 6-h after cardiac
arrest and underwent MTH, were included and reviewed.
Patients who were in shock on admission were also included
in this study. All patients were cooled to a target temperature
of 32 to 34 1C for 24 h. From a total of 90 patients, 30 of them
underwent PCI following MTH induction and were compared
to 70 patients who underwent MTH without PCI. A favorable
neurological outcome at discharge was observed in 30% of
patients in the PCI with MTH group, and in 22% of patients in
the MTH w/o PCI group (n.s.). The mortality rate was not
different between groups (PCI with MTH group 60% vs. MTH
w/o PCI 70%, n.s.). There was no increase in adverse events in
patients who underwent PCI with MTH compared to patients
with MTH w/o PCI (p¼0.054). No significant difference was
found in the rates of arrhythmias, infection, coagulopathy or
hypotension. Wolfurm et al. [13] reported that initiation of
MTH did not result in a prolonged door-to-balloon time in
patients after cardiac arrest due to acute myocardial infarc-
tion. MTH and coronary angiography are now recommended
for adult patients less than 75 years of age following cardiac
arrest related to VF in the presence of acute coronary
syndrome with STE- elevations [14].
Dumas et al. [15] assessed whether or not immediate
revascularization could improve the outcome in 435 patients
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cardiac origin. OHCA patients, in whom ROSC was achieved,
were admitted directly to the cardiac catheterization labora-
tory, regardless of ECG findings. A PCI was performed if either
a coronary artery occlusion or an unstable lesion(s) were
present. MTH was induced after the procedure. The popula-
tion was divided into 2 subgroups according to the post-ROSC
ECG (ST-segment elevation and other ECG patterns). The
primary outcome was hospital survival at discharge. At that
time, neurological status was assessed using the CPC score.
In the ST-segment elevation group (n¼134), at least 1 sig-
nificant coronary artery stenosis was found in 96% of
patients. PCI was successful in 90% of patients. In the 301
patients with other ECG patterns, 58% had at least one
significant coronary stenosis and PCI was performed in 31%
of patients. An increased hospital survival rate was present
both in patients with ST-segment elevation (54% with PCI and
31% without, or failed, PCI, po0.001) and in patients with
other ECG patterns (47% with PCI vs. 31% no or failed PCI,
po0.001) who underwent PCI. Multivariate analysis showed
successful PCI to be an independent predictor of survival,
regardless of the initial ECG pattern (OR 2.06, 95% CI, 1.16 to
3.66, po0.001). Univariate analysis revealed that MTH was
associated with a better prognosis (p¼0.006).
In the author’s cardiology department, urgent coronary
angiography is performed on all patients where myocardial
ischemia is the possible cause of cardiac arrest (i.e., all
patients with suspected acute coronary syndrome, patients
with left ventricle dysfunction, etc.).5. Mild Therapeutic Hypothermia and
In-hospital Cardiac Arrest (IHCA)
In January 2012, a study from Kory et al. reported results from
[16] a retrospective, historical controlled trial of IHCA patients
admitted to the Medical Intensive Care Unit before and after
implementation of MTH. They assessed its benefit in a select
population of IHCA patients matched with historical controls.
Between the years 2003 and 2009, they identified 118 patients
after an IHCA, which occurred in the Emergency Department
or after hospital admission. Patients with terminal illnesses,
defined as metastatic cancer, advanced treatment refractory
AIDS, class IV heart failure and patients with Do-Not-Resus-
citate orders, were not included in the study. All IHCA
patients meeting MTH criteria during the 3 year period prior
to the implementation of MTH served as the control group; all
IHCA patients meeting inclusion criteria who were admitted
after the implementation of MTH in 2006 served as the
intervention group. The primary outcome was good neurolo-
gical function (CPC score 1–2). A secondary outcome was best
neurological function after completion of MTH but prior to
discharge. Patients treated by MTH received continuous
sedation with fentanyl and midazolam, and 25 mg bolus of
atracurium at the start of cooling. A temperature range of
32–34 1C was maintained for 24 h.
A total of 33 IHCA patients met the inclusion criteria for
MTH during the study period. 17 patients formed the MTH
group and 16 patients formed the control group. Overall, 71%
of patients in the MTH group, and 69% of patients in thecontrol group, died prior to discharge (p¼0.87). A secondary
outcome (best neurological function prior to discharge) was
achieved in 41% of patients in the MTH group and in 31% of
patients in the control group (p¼0.55). Complication rates
(bleeding, pneumonia, acute renal failure, pulmonary edema,
sepsis) were similar in the two groups.
The main limitation of this study was its small sample size
and retrospective nature. The study focused on patients
admitted to the Medical Intensive Care Unit (which was not
a coronary care unit) and resulted in a population with a
majority (91%) of asystole and PEA rhythms. Therefore, the
results of this study may not reflect the full impact that MTH
can have on IHCA patients with VF/VT rhythms, which
deserves further study.
The causes of death after IHCA are different from those
after OHCA. Neurological injury is less likely to be the
primary cause of death among IHCA patients. Laver [17]
reported that 68% of OHCA patients die of neurological injury
vs. 23% of IHCA patients. Similarly, deaths due to multi-organ
failure occurred in 50% of IHCA, versus 9% of OHCA patients.
Outcomes from IHCA are consistently better when the first
monitored rhythm is VF/VT, rather than asystole/PEA. Unfor-
tunately, in the majority of studies, VF/VT was the first
monitored rhythm in only 20%–35% of IHCA survivors [18].6. Indications and Contraindications
MTH is indicated in adult OHCA survivors with ROSC within
60 min from the time of collapse, who remain unconscious
following ROSC, and whose initial rhythm was VF/VT (class I
recommendation, level of evidence B) [19].
Absolute contraindications are: hemorrhagic stroke con-
firmed by computed tomography, cardiac arrest due to trauma,
a Glasgow Coma Scale score of 8 or higher after ROSC, cardiac
arrest due to drug overdose, preexisting hypothermia with a
temperatureo34 1C, uncontrolled active bleeding, uncontrolled
hemodynamically unstable arrhythmias, and pregnancy. There
are also relative contraindications, such as known coagulopathy
and severe hypotension (mean arterial pressure o60mmHg)
not treatable by fluid infusion, vasopressors or invasive hemo-
dynamic support [20].7. Conclusion
MTH is now part of post-resuscitation care after a witnessed
cardiac arrest due to VF/VT, and offers evidence of improved
neurological outcomes and survival. The evidence of MTH
benefits in patients with non-shockable rhythms is less
certain. Induction of MTH does not delay reperfusion in
patients with acute coronary syndrome. It has been shown
that successful PCI is an independent predictor of survival,
regardless of the initial ECG pattern. There are many clinical
trials underway and there are expectations that the results
will provide a more definitive answer regarding the role
of MTH in patients with non-shockable rhythms, optimal
temperature management and the optimal duration of MTH.
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